Trials / Completed
CompletedNCT01776541
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 979 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adjuvanted H5N1 pandemic influenza vaccine | Comparison of two doses of aH5N1c vaccine |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-06-01
- Completion
- 2014-05-01
- First posted
- 2013-01-28
- Last updated
- 2015-02-03
- Results posted
- 2015-02-03
Locations
8 sites across 3 countries: United States, Australia, Thailand
Source: ClinicalTrials.gov record NCT01776541. Inclusion in this directory is not an endorsement.